Compound ID | 2817
Romsacin
Class: Antimicrobial peptide
| Details of activity: | Active against vancomycin-resistant (including biofilm) and -susceptible Enterococcus faecium, methicillin-resistant (including biofilm) and -susceptible Staphylococcus aureus, Staphylococcus haemolyticus (including biofilm), Staphylococcus lugdunensis, Staphylococcus saprophyticus, Staphylococcus capitis, Staphylococcus epidermidis (including biofilm) Enterococcus faecalis, Listeria monocytogenes, and Streptococcus uberis; likely cell wall synthesis inhibitor and membrane-active agent |
| Description: | Natural product from commensal Staphylococcus haemolyticus; bacteriocin/ lanthipeptide-type |
| Institute where first reported: | Department of Clinical Medicine, Faculty of Health Sciences, Research Group for Child and Adolescent Health, UiT The Arctic University of Norway, Tromsø, Norway |
| Year first mentioned: | 2023 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://journals.asm.org/doi/10.1128/spectrum.00869-23 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.